Table 2 Baseline echocardiographic profile.

From: Renal protective effect of sacubitril/valsartan in patients with heart failure

Characteristics Total Sacubitril/valsartan Valsartan P value
n = 274 n = 137 n = 137
IVS, mm 13(3) 13(3) 13(3) 0.75
LVEDD, mm 51(11) 52(11) 50(11) 0.16
LVPW, mm 13(3) 13(2) 12(3) 0.47
LV mass, g 323.4(151.8) 325(154.9) 319.5(146) 0.26
LVEF, % 54.0 ± 15.7 52.7 ± 15.7 55.4 ± 15.6 0.15
LVESD, mm 35(16) 37(16) 34(14) 0.04
RWT, cm 0.50(0.13) 0.49(0.15) 0.50(0.11) 0.25
LVMI, g/m2 194.5(84.0) 200.1(84.0) 193.4(85.7) 0.30
BSA, m2 1.63 ± 0.17 1.63 ± 0.17 1.62 ± 0.16 0.57
MS, n(%) 0 0 0 n/a
MR, n(%) 75(27.4) 41(29.9) 34(24.8) 0.42
AS, n(%) 6(2.2) 3(2.2) 3(2.2) 1.00
AR, n(%) 38 (13.9) 19(13.9) 19(13.9) 1.00
  1. IVS interventricular septum, LVEDD left ventricular end-diastolic diameter, LVPW left ventricular posterior wall, LV mass left ventricular mass, LVEF left ventricular ejection fraction, LVESD left ventricular end-systolic diameter, RWT relative wall thickness, LVMI left ventricular mass index, BSA body surface area, MS mitral stenosis, MR mitral regurgitation, AS aortic stenosis, AR aortic regurgitation.